Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Proton Therapy Boost Reduces Prostate Cancer Recurrence
Link ID 19951
Title Proton Therapy Boost Reduces Prostate Cancer Recurrence
Url http://www.medscape.com/viewarticle/712064?src=rss
Description A boost of proton therapy led to less biochemical recurrence of prostate cancer in a new study, although it was not a head-to-head comparison of proton therapy and conventional radiation technology. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Nov 11, 2009
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Customizing Treatment for Advanced NSCLC: Histology Matters
  Recent studies have found that specific histologic subgroups of NSCLC respond more favorably to particular therapies. This expert column focuses on the role of histology in selecting NSCLC therapies and improving patient outcomes. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


2. Thyroid Oncology Clinic Pulls Together Multidisciplinary Team
  Because several different specialties are involved in the treatment of thyroid cancer, patients sometimes hear conflicting advice. A clinic bringing them together has won an award for patient care. Medscape Medical News
Category:   Articles > Hematology-Oncology


3. Drug Shortages Predicted to Reach Record LevelsDrug Shortages Predicted to Reach Record Levels
  Critically needed drugs, including a large number of anticancer agents, are in short supply, delaying treatment or forcing patients to use alternatives -- if there are any. Medscape Medical News
Category:   Articles > Hematology-Oncology


4. Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therap
  Elderly patients with refractory multiple myeloma are tested with a regimen including the additive effect of bortezomib and pegylated liposomal doxorubicin. Clinical Lymphoma & Myeloma
Category:   Articles > Hematology-Oncology


5. PARP Inhibitors: Targeting the Defect, Not the Disease
  Prof. Ruth Plummer, a pioneer in poly (ADP-ribose) polymerase (PARP) inhibitor research, discusses the development of PARP inhibitors and their application in the treatment of a number of cancers. ecancer
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS